Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
about
Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.18F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.Treatment of uveal melanoma: where are we now?The role of tumor microenvironment in resistance to anti-angiogenic therapy.
P2860
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@en
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@nl
type
label
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@en
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@nl
prefLabel
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@en
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@nl
P2093
P2860
P50
P356
P1476
Phase II randomised discontinu ...... ntinib in metastatic melanoma.
@en
P2093
Aaron L Weitzman
Ali H Moussa
Frauke Schimmoller
Geoffrey I Shapiro
Harriet M Kluger
Michael S Gordon
Thomas A Samuel
P2860
P2888
P304
P356
10.1038/BJC.2016.419
P407
P577
2017-01-19T00:00:00Z
P6179
1048567126